2026 Preview: 10 Trends to Anticipate

IPD Analytics has released a new report, “2026 Preview: 10 Trends to Anticipate,” outlining the key market, regulatory, and clinical developments that will shape payer strategy in the year ahead. As 2026 approaches, payers are preparing for rapid shifts driven by evolving drug approvals, ongoing regulatory changes, and continued pressure in high-spend therapeutic areas.

The report highlights 10 critical topics for payers to monitor, including the impact of Medicare Drug Price Negotiation (DPN), most-favored-nation (MFN) agreements, pharmacy benefit manager (PBM) reform, 340B program changes, and updated FDA guidance on biosimilars.

With important approvals expected across ophthalmology, endocrinology, neurology, and pulmonary diseases, as well as anticipated generic and biosimilar launches, payers will need to refine formulary and utilization strategies to balance cost and access.